Skip to Content
Merck
All Photos(2)

Key Documents

MABS1987

Sigma-Aldrich

Anti-SREBP-1 Antibody, clone 20B12

clone 20B12, from rabbit

Synonym(s):

Sterol regulatory element-binding protein 1, SREBP-1, Sterol regulatory element-binding transcription factor 1

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rabbit

Quality Level

antibody form

unpurified

antibody product type

primary antibodies

clone

20B12, monoclonal

species reactivity

human

species reactivity (predicted by homology)

mouse (based on 100% sequence homology)

technique(s)

western blot: suitable

isotype

IgG

NCBI accession no.

UniProt accession no.

shipped in

ambient

target post-translational modification

unmodified

Gene Information

human ... SREBF1(6720)

General description

Sterol regulatory element-binding protein 1 (UniProt: Q9WTN3; also known as SREBP-1, Sterol regulatory element-binding transcription factor 1) is encoded by the Srebf1 (also known as Srebp1) gene (Gene ID: 20787) in murine species. SREBPs are a family of transcription factors that regulate lipid homeostasis by controlling the expression of a range of enzymes that are required for endogenous cholesterol, fatty acid, triacylglyceride, and phospholipid synthesis. The three SREBP isoforms known as, SREBP-1a, SREBP-1c, and SREBP-2, have different roles in lipid synthesis. It has been reported that SREBP-1c is mainly involved in fatty acid synthesis and insulin induced glucose metabolism. SREBP-2 is mainly involved in cholesterol synthesis. SREBP-1a isoform is reported to be involved in both of these pathways. Isoform SREBP-1A predominates in spleen, while isoform IC predominates in liver, adrenal gland, brain and adipose tissue and both IA and IC are found in kidney, thymus, testis, muscle, jejunum, and ileum. Expression of SREBP-1C in the liver is reported to be controlled in a circadian manner with a peak at ZT16. SREBPs are synthetized as inactive precursor proteins that are bound to the endoplasmic reticulum membranes and upon activation, the precursor is cleaved off in a two-step process to release the N-terminal active domain in the nucleus. Sterols are shown to inhibit the cleavage of the precursor protein and the mature nuclear form is rapidly catabolized, thereby reducing transcription. SREBP-1 binds to the sterol regulatory element-1 (SRE1 5′-ATCACCCCAC-3′), which flanks the low density lipoprotein receptor gene and some genes involved in sterol biosynthesis. Mice overexpressing processed isoform SREBP-1A in adipocytes show enlarged white and brown adipocytes, increased rate of fatty acid synthesis and secretion leading to a fatty liver. Mice lacking isoform SREBP-1C show a lack of up-regulation of several lipogenic enzymes in response to high insulin or LXR activation. (Ref.: Eberle, D et al. (2004) Biochimie 86(11); 839-48).

Specificity

Clone 20B12 recognizes SREBP-1 in multiple human tissues.

Immunogen

His-tagged recombinant fragment corresponding to 219 amino acids from the N-terminal region of murine sterol regulatory element-binding protein 1.

Application

Anti-SREBP-1, clone 20B12, Cat. No. MABS1987, a rabbit monoclonal antibody, detects SREBP-1 in human tissues by Western Blotting.
Research Category
Signaling
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected SREBP-1 in 10 µg of HEK293 cell lysates.

Quality

Evaluated by Western Blotting in HepG2 cell lysates.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected SREBP-1 in 10 µg of HepG2 cell lysates.

Target description

~120 kDa observed; 120.54 kDa calculated. Uncharacterized bands may be observed in some lysate(s).

Physical form

Format: Unpurified
Rabbit monoclonal antibody in cell culture supernatant without azide.
Unpurified

Storage and Stability

Stable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Other Notes

Concentration: Please refer to lot specific datasheet.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 2


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hong Lu et al.
Lipids in health and disease, 21(1), 46-46 (2022-05-26)
Hepatocyte nuclear factor 4α (HNF4α) and glucocorticoid receptor (GR), master regulators of liver metabolism, are down-regulated in fatty liver diseases. The present study aimed to elucidate the role of down-regulation of HNF4α and GR in fatty liver and hyperlipidemia. Adult
MiSung Kim et al.
JCI insight, 2(24) (2017-12-22)
Increased sugar consumption is a risk factor for the metabolic syndrome including obesity, hypertriglyceridemia, insulin resistance, diabetes, and nonalcoholic fatty liver disease (NAFLD). Carbohydrate responsive element-binding protein (ChREBP) is a transcription factor that responds to sugar consumption to regulate adaptive
Junhee Park et al.
Nature communications, 13(1), 5594-5594 (2022-09-24)
Insulin receptor (IR) signaling defects cause a variety of metabolic diseases including diabetes. Moreover, inherited mutations of the IR cause severe insulin resistance, leading to early morbidity and mortality with limited therapeutic options. A previously reported selective IR agonist without
Kyounghee Min et al.
eLife, 12 (2024-04-02)
Circulating lactate is a fuel source for liver metabolism but may exacerbate metabolic diseases such as nonalcoholic steatohepatitis (NASH). Indeed, haploinsufficiency of lactate transporter monocarboxylate transporter 1 (MCT1) in mice reportedly promotes resistance to hepatic steatosis and inflammation. Here, we
Antwi-Boasiako Oteng et al.
Molecular nutrition & food research, 63(19), e1900385-e1900385 (2019-07-22)
The mechanisms underlying the deleterious effects of trans fatty acids on plasma cholesterol and non-alcoholic fatty liver disease (NAFLD) are unclear. Here, the aim is to investigate the molecular mechanisms of action of industrial trans fatty acids. Hepa1-6 hepatoma cells

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service